Non-exclusive drug discount agreement for Tocilizumab
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tocilizumab (ATC-Code nach WHO: L04AC07)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No guaranteed purchase volumes; actual demand may be low or unpredictable, depending on doctor prescriptions and patien...
The buyer may terminate the procedure or the agreement early if exclusive discount agreements are concluded (typically...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Conclusion of non-exclusive discount agreements for Tocilizumab (ATC L04AC07)
- Supply of pharmaceutical products to AOK PLUS for patients in Saxony and Thuringia
Show full summary
This is a non-exclusive drug discount agreement (Rabattvereinbarung) for Tocilizumab (ATC L04AC07) under an open-house model. Interested pharmaceutical companies can submit participation requests from 03.12.2025 until 31.12.2026. The agreement ends on 31.12.2026. No minimum purchase quantities are guaranteed. The procedure is not a classic public procurement but a voluntary publication for transparency.
Risks
No guaranteed purchase volumes; actual demand may be low or unpredictable, depending on doctor prescriptions and patien...
The buyer may terminate the procedure or the agreement early if exclusive discount agreements are concluded (typically...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG
- Must have registered office in Germany, EU, or EEA (§9 Abs. 2 Satz 1 AMG)
Eligibility
- Must submit completed 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen' (declaration of no exclusion grounds)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Tocilizumab
Open-house model for concluding non-exclusive discount agreements for Tocilizumab. Covers pharmaceutical supply to AOK PLUS for Saxony and Thuringia.
Location
Duration
Category
Award Criteria
Deadline
Award details
No explicit award criteria provided. The agreement is based on acceptance of terms
likely price (discount) only.
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tocilizumab (ATC-Code nach WHO: L04AC07)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 20 Oct 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 690691-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No guaranteed purchase volumes; actual demand may be low or unpredictable, depending on doctor prescriptions and patien...
The buyer may terminate the procedure or the agreement early if exclusive discount agreements are concluded (typically...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications